TG THERAPEUTICS
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1993-01-01
- Employees
- 264
- Market Cap
- $3.5B
Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT02742090
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Seattle, Washington, United States
Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT02738775
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, San Antonio, Texas, United States
A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT02656303
- Locations
- 🇬🇧
TG Therapeutics Investigational Trial Site, Wolverhampton, United Kingdom
Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 603
- Registration Number
- NCT02612311
- Locations
- 🇬🇧
TG Therapeutics Investigational Trial Site, Wolverhampton, United Kingdom
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-14
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT02574663
- Locations
- 🇺🇸
TG Therapeutics Trial Site, Nashville, Tennessee, United States
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-08-28
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT02535286
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Seattle, Washington, United States
Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT02301156
- Locations
- 🇮🇱
TG Therapeutics Investigational Trial Site, Ashkelon, Israel
Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients
- First Posted Date
- 2014-06-16
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02164006
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Detroit, Michigan, United States
TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-04-01
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT02100852
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Memphis, Tennessee, United States
Ublituximab + Ibrutinib in Select B-cell Malignancies
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2022-10-24
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT02013128
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Vancouver, Washington, United States
© Copyright 2024. All Rights Reserved by MedPath